In Vivo Evolution of Candida auris Multidrug Resistance in a Patient Receiving Antifungal Treatment
The Journal of Infectious Diseases · 2025
DOI: 10.1093/infdis/jiaf394 ↗Kurz gefasst
Fallbericht in der Zeitschrift The Journal of Infectious Diseases, 2025. Verfasst von Tristan W Wang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology and Diagnostic Sciences, School of Dentistry, University of Maryland, Baltimore, Maryland, USA. Hauptthemen laut MEDLINE: Antifungal Agents, Candida auris, Candidiasis, Drug Resistance, Multiple, Fungal. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, NIH HHS, National Institute of Allergy and Infectious Diseases.
Abstract (Originalsprache)
Candida auris is associated with life-threatening invasive disease due to a high level of drug resistance. We present a clinical case of C. auris multidrug resistance development in a patient acquired during antifungal treatment. Five isolates were prospectively recovered from a lung transplant patient receiving antifungal therapy over a 1-year period. While isolates were initially only resistant to fluconazole, the terminal isolate became resistant to caspofungin and amphotericin B with significant increase in micafungin minimum inhibitory concentration. Sequencing of ERG11 and FKS1 genes identified mutations associated with fluconazole and echinocandin resistance in the multidrug-resistant isolate, underscoring the threat of therapy-induced development of resistance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncology and Diagnostic Sciences, School of Dentistry, University of Maryland, Baltimore, Maryland, USA.
- Department of Pathology, University of Maryland School of Medicine, Baltimore, Maryland, USA.
- Clinical Microbiology Laboratory, Laboratories of Pathology, University of Maryland Medical Center, Baltimore, Maryland, USA.
- Department of Microbiology and Immunology, School of Medicine, University of Maryland, Baltimore, Maryland, USA.
ORCID-Profile: Mary Ann Jabra-Rizk
Förderung
- NIAID NIH HHS
- NIH HHS
- National Institute of Allergy and Infectious Diseases
- University of Maryland Baltimore
- National Institutes of Health
Zitieren
APA
Wang, T. W., Putnam, N., Johnson, J. K., & Jabra-Rizk, M. A. (2025). In Vivo Evolution of Candida auris Multidrug Resistance in a Patient Receiving Antifungal Treatment. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiaf394
Vancouver
Wang TW, Putnam N, Johnson JK, Jabra-Rizk MA. In Vivo Evolution of Candida auris Multidrug Resistance in a Patient Receiving Antifungal Treatment. The Journal of Infectious Diseases. 2025. doi:10.1093/infdis/jiaf394
BibTeX
@article{Wang2025,
author = {Wang, Tristan W and Putnam, Nicole and Johnson, J Kristie and Jabra-Rizk, Mary Ann},
title = {In Vivo Evolution of Candida auris Multidrug Resistance in a Patient Receiving Antifungal Treatment},
journal = {The Journal of Infectious Diseases},
year = {2025},
doi = {10.1093/infdis/jiaf394}
}
EUVIMED